DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Information source: Bristol-Myers Squibb
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Psoriatic Arthritis

Intervention: Abatacept (Drug); Placebo (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: Bristol-Myers Squibb

Official(s) and/or principal investigator(s):
Bristol-Myers Squibb, Study Director, Affiliation: Bristol-Myers Squibb

Summary

The purpose of this study is to determine an optimal abatacept dosing regimen for the treatment of active arthritis due to psoriatic arthritis in patients who have had a prior inadequate response to disease-modifying antirheumatic drugs, including methotrexate and tumor necrosis factor alpha-blockade compounds.

Clinical Details

Official title: A Phase IIB, Multi-Dose, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome:

Long-term Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Drug-related AEs, AEs Leading to Discontinuation, and AEs of Interest

Short-term Period: Number of Participants With ACR 20 Response at Day 169

Secondary outcome:

Long-term Period: Percentage of Participants Achieving American College of Rheumatology (ACR) 20, ACR 50, ACR 70, ACR 90 Responses at Days 365 and 729

Long-term Period: Number of Participants With an Investigators Global Assessment (IGA) Score of Clear or Almost Clear at Days 365 and 729

Long-term Period: Mean Percentage of Change From Baseline in Target Lesion Score at Days 365 and 729

Long-term Period: Mean Change From Baseline in the Short-form 36 (SF-36), Version 2, Domain and Component Scores at Days 365 and 729

Long-term Period: Number of Participants Achieving A Reduction of At Least 0.3 Unit From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Days 365 and 729

Short-term Period: Number of Participants With Marked Abnormalities in Hematology

Short-term Period: Number of Participants With Marked Abnormalities in Hematology (Continued)

Short-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry

Short-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry (Continued)

Short-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry (Continued)

Short-term Period: Number of Participants With Marked Abnormalities in Urinalysis

Short-term Period: Number of Participants Who Died and With SAEs, AEs, AEs Leading to Discontinuation, SAEs Leading to Discontinuation, Drug-related AEs, and Drug-related SAEs

Short-term Period: Number of Participants With an IGA Score of Clear or Almost Clear at Day 169

Short-term Period: Mean Percentage of Change From Baseline in Target Lesion Score at Day 169

Short-term Period: Number of Participants With Positive Responses for Serum Levels of Abatacept-specific Antibodies (Anti-Abatacept-C)

Short-term Period: Mean Change From Baseline in the Mental Component Summary Score as Measured by the Short-form 36 at Day 169

Short-term Period: Mean Serum Concentrations of Abatacept

Short-term Period: Mean Serum Trough Concentrations (Cmin) of Abatacept

Short-term Period: Population Pharmacokinetic (POPPK) Analysis of the Pharmacokinetic (PK) Parameters

Short-term Period: Mean Change From Baseline in Physical Component Summary Score as Measured by the Short-form 36 at Day 169

Short-term Period: Number of Participants Achieving a Reduction of At Least 0.3 Unit From Baseline in HAQ-DI Scores at Day 169

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Key Inclusion Criteria:

- Meeting classification criteria for psoriatic arthritis for a duration of disease of

at least 3 months

- Prior failure (inefficacy or intolerance) of therapy with disease-modifying

antirheumatic drugs; if patient had prior failure of methotrexate, he or she must have been taking at least 15 mg per week for at least 2 months

- If recent failure(inefficacy or intolerance) of a tumor necrosis factor α-blockade

compound, participant must be washed out prior to first dose: 56 days for infliximab and 28 days for etanercept and adalimumab

- Disease activity as defined by a tender joint count of ≥3, swollen joint count of ≥3,

and clinically detectable synovitis at screening and Day 01 (prior to infusion)

- Active psoriasis with a qualifying target lesion ≥2 cm in diameter

- Able to undergo magnetic resonance imaging

- Use of appropriate birth control by women of child bearing potential (WOCBP)

Key Exclusion Criteria:

- WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for

the entire study period and for up to 10 weeks after the last dose of investigational product

- Women who are pregnant or breastfeeding or who plan to become pregnant or to start

breastfeeding during the duration of the study

- Women with a positive pregnancy test on enrollment or prior to investigational

product administration.

- Participants scheduled for or anticipating joint replacement surgery.

- Those with a recent history of clinically significant drug or alcohol abuse

- Concomitant illness that in the investigator's opinion is likely to require systemic

glucocorticosteroid therapy during the study (for example: moderate to severe asthma)

- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic,

pulmonary, cardiac, neurologic, ophthalmologic, or cerebral disease.

- Unwillingness or inability to undergo screening based on current local or country

guidelines/standards to evaluate the presence of cancer

- Cancer within the last 5 years

- Current malignancy or signs of possible malignancy detected by screening procedures

for which the workup to exclude malignancy has not been completed or malignancy cannot be excluded

- At risk for or history (within 3 years) of tuberculosis

- Any serious bacterial infection within the last 3 months, not treated and resolved

with antibiotics, or any chronic bacterial infection (such as, but not limited to, chronic pyelonephritis, osteomyelitis, and bronchiectasis)

- Evidence of active or latent bacterial or viral infection infections at the time of

potential enrollment

- Herpes zoster or cytomegalovirus resolving less than 2 months prior to signing

informed consent

- Receipt of any live vaccines within 3 months of the anticipated first dose of study

medication or anticipation of the need for a live vaccine at any time during and for 3 months after the duration of the study Long-term period participants: Must have met eligibility criteria for short-term period and completed short-term (24-week) period of the study

Locations and Contacts

Local Institution, Santa Fe 3000, Argentina

Local Institution, Hasselt 3500, Belgium

Local Institution, Leuven 3000, Belgium

Local Institution, Quebec G1W 4R4, Canada

Local Institution, Chambray Les Tours 37170, France

Local Institution, Lille 59037, France

Local Institution, Montpellier Cedex 5 34295, France

Local Institution, Frankfurt/Main 60590, Germany

Local Institution, Hamburg 22081, Germany

Local Institution, Hildesheim 31134, Germany

Local Institution, Napoli 80131, Italy

Local Institution, Potenza 85100, Italy

Local Institution, Reggio Emilia 42100, Italy

Local Institution, Amsterdam 1105 AZ, Netherlands

Local Institution, Lillehammer 2609, Norway

Local Institution, A Coruna 15006, Spain

Rheumatology Associates Of North Alabama, Huntsville, Alabama 35801, United States

Local Institution, Capital Federal, Buenos Aires 1015, Argentina

Desert Medical Advances, Palm Desert, California 92260, United States

Stanford University School Of Medicine, Palo Alto, California 94304, United States

Boling Clinical Trials, Upland, California 91786, United States

Joao Nascimento, Bridgeport, Connecticut 06606, United States

New England Research Associates, Llc, Trumbull, Connecticut 06611, United States

Sarasota Arthritis Research Center, Sarasota, Florida 34239, United States

Clinical Pharmacology Study Group, Worcester, Massachusetts 01610, United States

Justus Fiechtner, Md, Mph, Lansing, Michigan 48910, United States

St. Paul Rheumatology P.A., Eagan, Minnesota 55121, United States

Midwest Arthritis Center, Kalamazoo, Minnesota 49048, United States

Local Institution, St. John'S, Newfoundland and Labrador A1B 3E1, Canada

Arthritis Clinic & Carolina Bone & Joint, Pa, Charlotte, North Carolina 28210, United States

Deaconess Hospital, Cincinnati, Ohio 45219, United States

Health Research Of Oklahoma, Oklahoma City, Oklahoma 73103, United States

Altoona Center For Clinical Research, Duncansville, Pennsylvania 16635, United States

Rheumatic Disease Associates, Ltd., Willow Grove, Pennsylvania 19090, United States

Local Institution, Montreal, Quebec H2L 1S6, Canada

Local Institution, Trois-Rivieres, Quebec G8Z 1Y2, Canada

Local Institution, Cairns, Queensland 4872, Australia

Local Institution, Maroochydore, Queensland 4558, Australia

Local Institution, Rosario, Santa Fe 2000, Argentina

Chase, Walter F., Austin, Texas 78705, United States

Local Institution, Fitzroy, Melbourne, Victoria 3065, Australia

Seattle Rheumatology Associates, Seattle, Washington 98104, United States

Arthritis Northwest, Spokane, Washington 99204, United States

Local Institution, Panorama, Western Cape 7500, South Africa

Additional Information

BMS Clinical Trials Disclosure

For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm

Starting date: November 2007
Last updated: July 25, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017